Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TVTX
TVTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TVTX News
Travere Grants Equity Inducements to New Employees
3d ago
Newsfilter
Travere Grants Inducement Equity to New Employees
3d ago
Yahoo Finance
Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
Feb 04 2026
Newsfilter
Investigation into Potential Securities Violations at Travere Therapeutics
Jan 31 2026
Globenewswire
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
Jan 28 2026
PRnewswire
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
Jan 25 2026
Fool
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
Jan 24 2026
Fool
Palisades Acquires 137,768 Shares of Travere Therapeutics for $5.26 Million
Jan 24 2026
NASDAQ.COM
Travere Therapeutics (TVTX) FDA Review Extended to April 13
Jan 23 2026
Yahoo Finance
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
Jan 21 2026
Benzinga
Travere Therapeutics Under Investigation as FDA Extends Drug Review Timeline
Jan 14 2026
Globenewswire
Travere Therapeutics (TVTX) FDA Review Extended to April 13, Stock Drops 3.13%
Jan 14 2026
Benzinga
WeRide (WRD) Enables Robotaxi Booking via WeChat, Stock Rises 1.6%
Jan 14 2026
seekingalpha
Travere Therapeutics Faces 15% Stock Drop Due to FDA Review Delay for Filspari
Jan 14 2026
Fool
Travere Therapeutics Faces Setback as FDA Extends Filspari Review to April 13
Jan 14 2026
NASDAQ.COM
S&P 500 Index ($SPX) Declines 0.19% as Software Stocks Retreat
Jan 14 2026
NASDAQ.COM
Show More News
